Eagle's Sassouni pointed out that
since the big
drug companies are losing billions of dollars every year to
generic versions and have little to spend on their own research and development, they are looking to buy smaller biotechnology
companies that are developing their own products.
Even after completing an associate degree, graduates will have to stay current with changes occurring in the industry or with particular pharmaceutical
companies,
since new
drugs and
generic brands are always entering the market.